The findings highlight key trends in the efficacy of antidiabetic drugs for AD and AD-related dementia, particularly the promising role of GLP1 agonists or metformin, and suggest potential avenues for repurposing these drugs as treatments for AD. This evidence concerns the gene GCG and Alzheimer disease.